What's the latest with health-tech/bio-tech companies? Exscientia, Cellugy, Ensysce paving an awesome path.
Oxford-based Exscientia uses AI to accelerate delivery of new treatments; gets €3.44M from Gates Foundation
In a recent development, Exscientia announced that it has received $4.2M (nearly €3.44M) grant from Bill & Melinda Gates Foundation. With this investment, the pharmatech company will apply its AI-driven Cetaur platforms to the discovery of the new generation of therapeutic targets and leads.
Oxford-based leading pharmatech company Exscientia deploys Artificial Intelligence to drive drug discovery. It is claimed to be a pioneer in using AI to design a novel molecule to enter the clinic. Now, this company has raised funding to identify new targets and leads for a slew of ailments such as malaria, tuberculosis, and non-hormonal contraception.
https://siliconcanals.com/news/startups/oxford-ai-startup-exscientia-funding/
Danish startup Cellugy nabs €2.38 million to make eco-friendly packaging from surplus sugars
Cellugy, the Danish-based biotech startup replacing single-use plastics with 100% natural bio-cellulose, announces the securement of €2.38 million in seed round funding from the European Innovation Council Accelerator Pilot Phase 2. The company, which was founded in 2018 by Isabel Álvarez-Martos, Deby Fapyane, and Paruntungan Sihombing, has been developing a biomaterial to sustainably replace fossil-based plastic in the packaging industry. The grant will be used to scale up the production of EcoFLEXY, focusing on technical optimization strategies, a pilot plant setup, and relevant pre-deployment activities. https://www.eu-startups.com/2020/12/danish-startup-cellugy-nabs-e2-38-million-to-make-eco-friendly-packaging-from-fruit-sugars/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+eu-startups+%28EU-Startups%29
Ensysce Biosciences Secures $60M in Funding
Ensysce Biosciences Inc., a San Diego, CA-based clinical phase company launching two new classes of novel opioids designed to treat severe pain, and eliminate opioid misuse, abuse and overdose, secured $60m in funding.
Ensysce will use the funds to progress the clinical development of PF614, a first in class Trypsin Activated Abuse Protection (TAAPTM) extended-release opioid prodrug, and its Multi-Pill Abuse Resistance (MPARTM) overdose protected counterpart, PF614-MPARTM. The company is led by Lynn Kirkpatrick, PhD, CEO, and Richard Wright, CBO, and Geoff Birkett, CCO. https://www.finsmes.com/2021/01/ensysce-biosciences-secures-60m-in-funding.html